Rangeley Capital LLC bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 239,000 shares of the company's stock, valued at approximately $2,827,000. Roivant Sciences accounts for about 2.5% of Rangeley Capital LLC's portfolio, making the stock its 12th biggest position.
Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Roivant Sciences by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after buying an additional 2,404,232 shares during the period. State Street Corp boosted its holdings in shares of Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company's stock valued at $225,737,000 after purchasing an additional 1,118,561 shares during the period. Geode Capital Management LLC grew its stake in Roivant Sciences by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 7,771,831 shares of the company's stock worth $91,968,000 after purchasing an additional 26,727 shares in the last quarter. Norges Bank bought a new position in Roivant Sciences in the fourth quarter worth approximately $52,443,000. Finally, Pertento Partners LLP lifted its holdings in shares of Roivant Sciences by 22.8% in the 4th quarter. Pertento Partners LLP now owns 3,484,918 shares of the company's stock worth $41,227,000 after buying an additional 646,865 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.
Read Our Latest Stock Analysis on ROIV
Roivant Sciences Price Performance
Shares of ROIV stock traded up $0.16 during mid-day trading on Tuesday, hitting $9.42. 1,664,542 shares of the stock traded hands, compared to its average volume of 5,332,270. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $13.06. The stock has a market cap of $6.72 billion, a P/E ratio of -62.95 and a beta of 1.25. The stock's fifty day moving average is $10.58 and its two-hundred day moving average is $11.31.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, equities analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Insider Activity at Roivant Sciences
In other news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the business's stock in a transaction dated Monday, January 13th. The stock was purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the acquisition, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,395,541 shares of company stock valued at $15,028,538 in the last three months. 7.90% of the stock is owned by insiders.
Roivant Sciences Company Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
